Skip to main content

Table 4 Secondary safety outcomes

From: Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

  ARNI
(N = 87)
Standard treatment
(N = 100)
p-value
Mean changes of key laboratories and vital signs
 Systolic blood pressure (mmHg)  + 0.55 ± 16.3  + 2.88 ± 18.1 0.355
 Diastolic blood pressure (mmHg) -0.24 ± 9.4 -0.50 ± 11.2 0.864
 Serum sodium (mEq/L) + 0.54 ± 3.0 + 0.20 ± 3.6 0.655
 Serum potassium (mEq/L)  + 0.17 ± 0.5  + 0.22 ± 0.8 0.612
 Serum creatinine (mg/dL)* + 0.04 (0.28) + 0.14 (0.56)  < 0.001
Clinical signs and symptoms for safety outcomes (%)
 Dry cough 7 (8.0) 11 (11.0) 0.062
 Angioedema 0 0
 Hypotension** 12 (13.8) 5 (5.0) 0.043
 Symptomatic orthostatic hypotension*** 22 (25.3) 13 (13.0) 0.032
 Asymptomatic orthostatic hypotension*** 18 (20.7) 11 (11.0) 0.068
  1. ARNI = angiotensin receptor/ neprilysin inhibitor
  2. *Reported as median (interquartile range)
  3. **Fisher Exact test
  4. ***Orthostatic hypotension: a physical finding defined by the American Autonomic Society and the American Academy of Neurology as a systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing